To learn more, please call our Research Department at (513) 936-5388 or (888) 649-4800. Or email abradley@ohcmail.com or jmcguire@ohcmail.com
- ADJUVANT STUDIES
- Study number:
- ECOG E2805 CTSU
- Protocol title:
- A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
- Status:
- Open
- ADVANCED/METASTATIC/FIRST LINE
- Study number:
- GU 43 SCRI
- Protocol title:
- A Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients with Advanced Clear Cell Renal Carcinoma
- Status:
- Open -cohort B only open to enrollment
-
- METASTATIC, RELAPSED/REFRACTORY
- Study number:
- GU 43 SCRI
- Protocol title:
- A Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients with Advanced Clear Cell Renal Carcinoma
- Status:
- Open
- Study number:
- GU 44 SCRI
- Protocol title:
- A Phase I/II Trial of Sorafenib (Nexavar) and RAD001 (Everolimus) in the Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma
- Status:
- Open
- Study number:
- GU 56 SCRI
- Protocol title:
- A Phase II Trial of Pazopanib in Patients with Metastatic Renal Cell Carcinoma Previously Treated with sunitinub or bevacizumab
- Status:
- Open